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Aetiological diagnosis for patients with schizophrenia was long thought to be impossible. 
However, genomic abnormalities with clear causal relevance can now be identified in a 
consistent minority of cases using chromosomal microarray analysis (CMA; also known as 
array Comparative Genomic Hybridization or array-CGH).  Analogous to a karyotype but with 
dramatically improved genome-wide resolution, CMA can inform diagnosis and clinical 
management by identifying sub-microscopic segments of missing (deleted) or additional 
(duplicated) chromosomal material known as copy number variants (CNVs).  CMA is 
sensitive, reliable, and widely available in clinical laboratories around the world, including 
major medical centres in the developing world.  Costs are competitive with other 
investigations such as neuroimaging.  CMA is now a standard first-line diagnostic test for 
intellectual disability and autism where 10-20% of affected individuals have a clinically-
relevant deletion or duplication (1).   Widespread application of CMA testing in these 
populations has increased confidence in diagnostic interpretation, enhanced the prognostic 
evidence base, and facilitated research progress (2).  In our view, the time has come to 
translate replicated research findings with proven clinical utility into routine diagnostic 
practice for patients with schizophrenia. 
The rationale for chromosomal microarray testing in schizophrenia 
Clinically-relevant deletions or duplications are present amongst individuals with 
schizophrenia with a collective prevalence of 5% or more (3-5).  These encompass three 
broad groups of CNVs, each of which can occur de novo or can be inherited: (A) 22q11.2 
deletions (~1% of schizophrenia; lifetime schizophrenia risk amongst deletion carriers ~25% 
(6)); (B) other recurrent deletions and duplications associated with schizophrenia, e.g. 
1q21.1 deletions, 15q11-q13 duplications (~3-4% collectively of schizophrenia); (C) other 
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individually rarer abnormalities.  The first study of CMA application in a community-based 
sample of schizophrenia showed that 1 in 13 patients within a single geographical 
catchment had a clinically-relevant deletion or duplication: diagnostic yield 8.1% (95% CI 
5.2–12.2%)(7). Those with pathogenic genetic anomalies diagnosed via CMA were 
indistinguishable from the remainder of patients with respect to basic clinical variables.  
Hence, if CMA is only offered to patients with additional features such as intellectual 
disability or dysmorphology, many individuals with clinically-significant deletions or 
duplications will remain undiagnosed.   
Maximising clinical utility  
Identification of a pathogenic CNV can improve holistic physical and mental health care for 
patients with schizophrenia.   Taking the example of 22q11.2 deletion syndrome, there are 
clinical practice guidelines to aid lifetime management (8).  These include clear 
recommendations for baseline medical assessments (e.g. cardiac and immunological 
assessments) and annual checks (e.g. thyroid function tests and serum calcium monitoring).   
These CNV-specific assessments frequently uncover hidden health problems in adult 
patients, leading to a range of interventions from dietary advice to pharmacological 
treatments which significantly improve well-being and reduce risk of serious complications.  
Diagnosis of 22q11.2 deletion syndrome can also influence psychiatric treatment:  
antipsychotic choice may be modified according to safety profiles; seizure risk can be 
reduced by early use of anticonvulsants and by identifying and treating hypocalcaemia.  For 
other recurrent schizophrenia-associated CNVs, there are systematic efforts to establish 
similar evidence bases (9-11).  Genetic counselling after diagnosis of any clinically-significant 
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deletion or duplication is important because offspring are at 50% risk of inheriting the CNV, 
with inherent medical, neurodevelopmental and psychiatric implications.   
Recognising limitations  
Genomic abnormalities interact with biological and social factors to mediate psychiatric risk, 
and an overly reductionist approach is unrealistic.  However, this complexity is not unique to 
psychiatric illness or schizophrenia.  As for most genetic diagnoses, the clinical problems 
associated with pathogenic deletions and duplications vary from person to person, even 
within families. Variable expression encompasses physical manifestations, cognitive 
impairments and psychiatric symptoms, and it is difficult to predict which individuals with 
clinically-significant CNVs will experience specific problems in each area.  For very rare CNVs, 
limited prognostic information will be available until more cases are diagnosed.  A further 
limitation is that some CMA findings will be reported as variants of uncertain significance 
(VUS) when there is insufficient current evidence to classify a CNV as either benign or 
pathogenic.   
Practicalities of chromosomal microarray testing for patients with schizophrenia 
CMA testing and genetic diagnosis have been shown to be desirable and acceptable 
amongst patients with schizophrenia and their families, even amongst the majority who did 
not receive a genetic diagnosis (12;13).  The process of obtaining informed consent is in 
essence no different for patients with schizophrenia than for any other population, once 
capacity has been evaluated.  A simple pre-test discussion should outline the purposes, 
benefits and limitations of testing (Table 1).  It is desirable to involve family members so 
that awareness is shared amongst individuals for whom test results are potentially relevant.  
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However, lack of availability of family members should not preclude testing that may be of 
great individual benefit.   
Looking ahead 
A genetic diagnosis can have multiple practical and psychological values for patients, their 
partners, relatives, clinicians and wider society.  Further research that integrates CNV 
diagnosis with cognitive neuroscience has the potential to illuminate diverse pathways from 
risk to symptoms (14, 15).   The benefits of genetic diagnosis and risks inherent in under-
investigation considerably outweigh limitations of CMA testing.  CMA is a natural step in the 
evolution of biologically-informed clinical management of schizophrenia – clinical exome 
and whole genome sequencing is on its way (16).  This eventuality mandates a concerted 
effort to address knowledge gaps, remove discriminatory barriers, and increase 
opportunities for individualized care for adults with severe mental illness.   
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TABLE 1: CMA testing for patients with schizophrenia – aims, benefits, limitations, strategies 
AIMS Identification of causal factors 
Awareness of associated 
medical risks 
Tailored psychiatric care Genetic counselling 
Potential 
benefits  
 Detection of clinically-
significant deletion or 
duplication (CNV) in 5-8% of 
patients with schizophrenia 
 Surveillance and 
interventions for treatable 
conditions e.g. cardiac, 
endocrine, neurological 
 Reduction in health 
inequalities, improvement 
in quality of life 
 Enhanced understanding of 
the patient’s illness 
 Improved safety and 
effectiveness of treatments 
for schizophrenia 
 Individualised, evidence-
based counselling 
 Education and 
empowerment  
 Genetic testing options for 
at-risk relatives  
Limitations and 
challenges 
 No clinically-significant CNV 
in the majority of cases 
 Variants of uncertain 
significance  
 Incidental findings 
 Limited evidence base for 
rare CNVs  
 Variability in clinical 
expression  
 Few specific treatment 
recommendations for rare 
CNVs 
 Adjustment of patient, 
family and clinician to new 
knowledge 
 Questions around childhood 
testing and prenatal testing 
Strategies   Submission of CNV data to 
international databases to 
enhance interpretation of 
variants 
 Genome sequencing to 
increase diagnostic yield 
 Submission of phenotype 
data to international 
databases to enhance 
prognostic evidence base 
 Research into medical 
comorbidities, surveillance 
approaches, interventions 
and outcomes 
 Continue standard 
treatments unless change 
indicated 
 Research into psychiatric 
presentations, treatment 
responses and outcomes 
 Potential for new aetiology-
specific, mechanism-
informed therapies 
 Enhanced liaison between 
psychiatry and clinical 
genetics  
 Clinician education to 
increase confidence in 
initiating testing, pre-test 
discussion, managing results  
 
